Browse the evidence

Phentermine-topiramate produces greater weight loss than GLP-1 receptor agonists, but GLP-1 agonists carry a higher risk of adverse events.

If you are looking for the maximum possible weight loss number, phentermine-topiramate may outperform GLP-1 drugs like semaglutide. However, this comes with a higher risk of side effects. GLP-1s offer a better safety profile regarding adverse events and provide proven cardiovascular protection, making them a preferred choice for patients with heart disease risks despite slightly lower weight loss efficacy.

Intragastric balloons (IGB) are effective for weight loss but carry risks of dehydration, readmission, and reintervention, with saline-filled balloons outperforming air-filled ones.

If lifestyle changes haven't worked, an intragastric balloon can be a helpful bridge. Choose a saline-filled balloon over an air-filled one for better results. Be prepared for a 6-12 month commitment and take prescribed stomach acid reducers to prevent discomfort. The risk of serious complications is low, but dehydration is a common side effect.

SGLT2 inhibitors and GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) provide clinical benefits in obesity-related HFpEF, including symptom improvement and potential reverse cardiac remodeling, independent of or in addition to weight loss.

If you have obesity and heart failure with preserved ejection fraction, ask your doctor about SGLT2 inhibitors (like dapagliflozin) or GLP-1 agonists (like semaglutide). These drugs not only help with weight but also directly protect the heart by reducing inflammation and stiffness, improving symptoms and outcomes.

Discontinuation of obesity management medications (OMMs) such as tirzepatide or semaglutide leads to substantial weight regain and partial reversal of cardiometabolic improvements, indicating that sustained treatment is required to maintain health benefits.

If you stop taking your obesity medication (like tirzepatide or semaglutide), you will likely regain most of the weight you lost, even if you keep your diet and exercise habits. To keep the health benefits, you generally need to stay on the medication long-term.

Incretin-based therapies (GLP-1 and GIP/GLP-1 RAs) produce clinically significant weight loss and improve weight-related comorbidities, but their implementation is hindered by high costs, insurance coverage barriers, supply shortages, and gastrointestinal adverse events.

Incretin-based therapies like semaglutide and tirzepatide are highly effective for weight loss and improving health conditions like diabetes and heart disease. However, access is difficult due to high costs, insurance restrictions, and supply shortages. Side effects like nausea are common but often improve over time. Patients should work with pharmacists to navigate coverage and manage side effects through careful dosing.

Tirzepatide treatment (5-15 mg weekly) significantly reduces serum uric acid (SUA) levels in adults with obesity or overweight, with weight reduction explaining 72.7% of this effect.

If you have obesity or overweight and are concerned about gout or high uric acid, tirzepatide (a once-weekly injection) can significantly lower your uric acid levels. Most of this benefit comes from the weight loss it causes, but it may also have direct effects. This makes it a potentially useful tool for managing gout risk in people with obesity, in addition to helping with weight loss.

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalization in type 2 diabetes patients, while also reducing liver fat content and improving liver enzymes in those with MASLD.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs are proven to significantly lower your risk of heart failure and death, and they also help reduce fat in your liver. They are a key part of modern care for this condition.

GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) reduce major adverse cardiovascular events (MACE) and promote histological resolution of MASH in patients with T2D and MASLD.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about GLP-1 receptor agonists (like semaglutide or liraglutide). These drugs are proven to significantly lower your risk of heart attacks and strokes, and they can even reverse liver inflammation (MASH) in some patients. They are a key part of modern care for this condition.

GLP-1 receptor agonists (GLP-1 RAs) produce modest but statistically significant reductions in systolic blood pressure (SBP) in patients with type 2 diabetes and/or obesity, primarily through weight loss, improved endothelial function, and renal sodium excretion.

If you have type 2 diabetes or obesity, GLP-1 medications like semaglutide or liraglutide can help lower your blood pressure slightly. However, they are not strong enough to replace your blood pressure medication if your numbers are high. The real value is that they help with weight and blood sugar at the same time. Talk to your doctor about whether the added benefits outweigh the cost and potential stomach side effects.

Tirzepatide reduces major adverse cardiovascular events (MACE), including acute myocardial infarction and all-cause mortality, in patients with Type 2 Diabetes.

For patients with Type 2 Diabetes, Tirzepatide offers significant cardiovascular protection, reducing the risk of heart attack, stroke, and death by approximately 40% compared to other GLP-1 agonists. This makes it a preferred choice for patients with high cardiovascular risk.

GLP-1 receptor agonists (GLP-1RAs) provide cardiovascular protection by reducing systemic inflammation, improving endothelial function, and reducing epicardial adipose tissue (EAT) volume, independent of weight loss.

If you have Type 2 Diabetes or Obesity, GLP-1 receptor agonists (like Ozempic, Wegovy, or Victoza) offer heart protection beyond just weight loss. They reduce inflammation in your blood vessels and shrink fat around your heart (EAT), which lowers your risk of heart disease. This benefit happens even if you don't lose a huge amount of weight. Talk to your doctor about whether these medications are right for your cardiovascular health.

Tirzepatide treatment for obesity is associated with a very low incidence of macronutrient malnutrition and vitamin deficiency adverse events, with fewer than 1% of patients discontinuing treatment due to nutritional status concerns.

If you are taking tirzepatide for obesity, the risk of developing serious nutritional deficiencies or malnutrition is very low, especially if you follow the recommended dietary counseling. The study showed that fewer than 1% of patients had adverse events related to malnutrition. To stay healthy, focus on the recommended diet (high protein, balanced macros) and attend your lifestyle counseling sessions.

Tirzepatide and Mazdutide, as dual-receptor agonists, offer superior glucose-lowering and weight loss efficacy compared to conventional GLP-1RAs, but their high cost and lack of reimbursement limit their overall recommendation status.

Tirzepatide and Mazdutide are powerful dual-receptor agonists that offer superior glucose and weight loss benefits compared to conventional GLP-1RAs. However, their high cost and lack of insurance coverage in China make them less accessible. Patients should discuss these options with their doctors, considering both efficacy and affordability. If cost is a barrier, Semaglutide and Dulaglutide are strong alternatives with established cardiovascular benefits.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces statistically significant reductions in HbA1c and body weight in patients with type 2 diabetes and obesity, outperforming several existing antidiabetic classes including GLP-1 agonists and insulin.

Tirzepatide is a once-weekly injection that significantly lowers blood sugar and helps with weight loss in people with type 2 diabetes and obesity. It works by mimicking two natural hormones (GIP and GLP-1). Clinical trials show it is more effective than some existing diabetes medications and GLP-1 drugs alone. Common side effects include gastrointestinal issues, which are often worse at higher doses, so doctors usually start with a low dose and increase it slowly. It is not recommended for pregnant women.

GLP-1 receptor agonists reduce the formation of atherosclerotic plaques and lower inflammatory markers in patients with type 2 diabetes.

GLP-1 medications may help protect against heart disease by reducing the buildup of plaque in arteries and lowering inflammation, in addition to their weight loss effects.

Dual GIP/GLP-1 agonism (tirzepatide) offers cardiovascular safety comparable to or better than insulin glargine, with no increased risk of major adverse cardiovascular events (MACE).

For patients with Type 2 Diabetes and heart disease concerns, tirzepatide has been shown to be cardiovascularly safe, with no increased risk of heart attacks or strokes compared to insulin glargine. This makes it a viable option for those prioritizing heart health alongside glucose control.

Protein intakes exceeding 2.0 g/kg/day do not provide additional lean body mass gains in the absence of concurrent resistance training.

Eating more than 2 grams of protein per kilogram of body weight will not build muscle if you are not lifting weights. Focus on resistance training first; protein alone is insufficient for growth without it.

The vast majority (approx. 92%) of daily protein intake in young adults comes from whole-food sources rather than supplemental protein isolates, regardless of training status.

You get almost all your protein (92%) from regular food, not supplements. This is typical for active young adults. You do not need to buy protein powder to meet your needs; focus on getting protein from meat, dairy, eggs, and plant sources.

Ramadan fasting significantly impairs anaerobic power (Wingate peak and mean power) and upper-body strength (bench press), but does not significantly affect lower-body maximal strength (leg press), explosive power (countermovement jump), or isometric strength (handgrip).

During prolonged fasting, expect a drop in your ability to perform high-intensity, short-duration efforts (like sprints or heavy upper-body lifts). Your leg strength and vertical jump may remain stable, but prioritize recovery and nutrition strategies for anaerobic tasks.

Resistance training-induced skeletal muscle hypertrophy is associated with the differential regulation of 110 non-coding RNA (ncRNA) genes, which mediate growth via specific cell types including leukocytes, satellite cells, and pericytes.

This research confirms that muscle growth is not just about mechanical tension but involves complex genetic regulation via non-coding RNAs. For the average lifter, this means individual genetic variability plays a huge role in response to training (only 61% were 'responders' in this study). While there is no direct intervention yet, this highlights that 'non-responders' may have different molecular profiles, suggesting future personalized training or nutritional strategies could be based on these biomarkers.

Micellar casein provides a sustained, slow-release amino acid profile, whereas free L-amino acids (L-AAs) and casein glycomacropeptide (CGMP) result in rapid, transient absorption peaks.

If you want a slow, steady drip of amino acids (like before bed or during long fasting windows), choose micellar casein. If you need a rapid spike of amino acids (like immediately post-workout), free amino acids or CGMP will deliver them much faster than casein. Note that CGMP does not act like casein despite being a peptide.

Visceral adipose tissue (VAT) accumulation exacerbates insulin resistance and increases fasting blood glucose and HbA1c, whereas brown adipose tissue (BAT) activation improves glucose regulation and insulin sensitivity.

Focus on reducing visceral fat (belly fat) rather than just total body weight. Strategies that activate brown fat (like cold exposure or specific exercises) or reduce visceral fat (through diet/exercise) are more effective for blood sugar control than general weight loss alone.

For patients with poorly controlled type 2 diabetes on basal insulin, using FreeStyle Libre (FSL) continuous glucose monitoring systems reduces overall lifetime healthcare costs and increases quality-adjusted life years (QALYs) compared to self-blood glucose monitoring (SBGM).

If you have type 2 diabetes, take basal insulin, and your blood sugar is not well controlled (HbA1c > 8%), switching from finger-prick testing to a flash glucose monitor (like FreeStyle Libre) is likely to save your healthcare system money and improve your long-term health and quality of life. This is because it helps prevent dangerous low blood sugar events and long-term complications like heart disease or kidney failure, while also being less painful and inconvenient than daily finger pricks.

Achieving optimal control of multiple risk factors (lifestyle and metabolic) in type 2 diabetes can restore life expectancy to levels comparable to individuals without diabetes.

If you have type 2 diabetes, focus on controlling your risk factors (blood sugar, blood pressure, lipids, smoking, diet, and exercise). Doing so can add 6-9 years to your life compared to poor management and may even bring your life expectancy in line with someone who doesn't have diabetes.